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Delirium is a frequent complication in medically ill elderly patients that is associated with serious adverse outcomes including
increased mortality. Delirium risk is linked to older age, dementia, and illness that involves activation of inflammatory responses.
IGF-I is increasingly postulated as a key link between environmental influences on body metabolism with a range of neuronal
activities and has been described as the master regulator of the connection between brain and bodily well-being. The relationships
between IGF-I and ageing, cognitive impairment and inflammatory illness further support a possible role in delirium pathogenesis.
Five studies of IGF-I in delirium were identified by a systematic review. These conflicting findings, with three of the five studies
indicating an association between IGF-1 and delirium occurrence, may relate to the considerable methodological differences
in these studies. The relevance of IGF-I and related factors to delirium pathogenesis can be clarified by future studies which
account for these issues and other confounding factors. Such work can inform therapeutic trials of IGF-I and/or growth hormone
administration.
1. Introduction
Delirium is an etiologically diverse organic cerebral syn-
drome of acute onset (over hours to days) characterized by
a fluctuating course that includes alterations in level of con-
sciousness, psychomotor behavior, attention and cognition,
as well as variable expression of various neuropsychiatric
disturbances [1]. It is a frequent complication in elderly
hospitalized patients, affecting around 30% [2]. Despite this
frequency, delirium is frequently misdiagnosed or missed,
and considerable uncertainty remains regarding optimal
management [3–5]. Delirium is associated with a range of
adverse outcomes, including, longer hospital stays, greater
healthcare costs, reduced subsequent functional indepen-
dence, and increased mortality [6]. The pathophysiology
of delirium has been understudied [5], and, in particular,
it remains uncertain how such a wide range of potential
etiologies, many of which involve pathology at peripheral
body locations and without clear links to CNS function,
can produce such a consistent complex neuropsychiatric
picture that reflects generalized brain dysfunction. Central
to understanding delirium is understanding mechanisms
by which body and brain well-being are linked and, in
particular, how brain responses to bodily homeostatic stress
is mediated.
2. Delirium and the Aging Process
Advanced age is an independent risk factor for developing
delirium with increasing risk corresponding to increasing
agedness, for example [7–11]. Dementia is another impor-
tant risk factor for delirium that is also age-related with
a prevalence of 1% at the age of 60 that doubles with each
additional five years of age [12]. Approximately 50% of
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patients with delirium have comorbid dementia [13], and the
presence of dementia increases the risk of delirium by fivefold
[11, 14, 15]. Even mild cognitive decline increases the risk for
delirium [16]. Patients with dementia are more vulnerable
to delirium at lower levels of medical morbidity that
nondemented ones. In addition, stroke confers an eightfold
increase in the risk for delirium [17] with the incidence of
delirium in stroke patients varying from 13% to 48% [18].
Similarly, increasing age is associated with greater burden
of morbidity and diminished tolerance of medications with
the number and type of medication implicated as a principal
cause of delirium in 12 to 39% of cases [19, 20]. In essence,
almost any dysfunction or damage of the brain resulting from
acute illness, trauma, sepsis, medication or, other insults can
cause delirium [21].
It is increasingly recognized that the traditional con-
cept of delirium as a transient reversible condition is not
evidenced in many older patients [9, 22–24] for whom
more persistent cognitive and functional impairments are
common [21, 25]. The irreversibility of some clinical features
[9, 26], the emerging evidence of a relationship with
dementia [27, 28], and the poor prognosis independent
of premorbid factors suggest that the pathophysiological
processes that underpin the syndrome of delirium can also be
associated with more permanent decline of cerebral function
andmay overlap with those of dementia. Delirium is a highly
heterogeneous condition regarding causation with typically
multiple contributing etiological factors in any single case
and single-etiology delirium the exception rather than the
rule [29]. Inevitably, a number of different mechanisms
have been proposed to explain the pathophysiology of
delirium:the effects of medication, direct neurotoxicity of
the delirious state due to changes in inflammatory and
glucocorticoid systems [21, 30–32]. More recently, studies
have focused on the possible role of alterations in hormones
with neuroprotective properties such as insulin-like growth
factor I (IGF-I).
3. The Neurobiology of IGF-I
Insulin-like growth factor I (IGF-I) is one of a family of
peptides that have important regulatory roles in bodily
growth and related metabolic functions, as well as a variety
of brain functions. IGF-I has been postulated as particularly
important within this family due to its unusually complex
regulatory neurobiology whereby; (a) IGF-I can be produced
by any cell type with the liver as the primary site of
production for circulating IGF-I [33], (b) IGF-I receptors are
found on nearly all body cell types, and most brain regions
express IGF-I immunoreactivity and possess IGF-I binding
sites [34], (c) serum levels are extremely high and crucially
linked to a range of CNS functions, (d) it is regulated by a
the complex interplay of multiple binding proteins (IGFBPs),
and (e) IGF-I unilaterally stimulates other growth factors
many of which act downstream to IGF-I such that it appears
to be a final common pathway for protein networks [35].
IGF-I receptors are highly expressed in the cells that
constitute the blood-brain barrier and, in addition to reg-
ulating the integrity of this barrier, provide the route by
which serum IGF-I accesses the brain. This well developed
linkage mechanism between brain and peripheral activity of
this key regulator of body metabolism, and CNS functional
integrity has stimulated studies that explore the role of IGF-I
in mediating the neuroprotective effects of activities such as
exercise and increasingly highlight how interactions between
IGF-I and other key metabolic regulators such as insulin
allow for the brain and body to coordinate responses to
environmental challenges. IGF-I regulates carbohydrate, fat,
and protein metabolism, and serum levels are increased by
increasing muscle mass by exercise [36]. This increase in
serum IGF-I is communicated to the CNS which can then
adapt with better motor coordination and enhanced CNS-
controlled anabolic activity. Interestingly, evidence has indi-
cated a protective effect of exercise upon risk for cognitive
disturbance including delirium [37].
IGF-I is produced locally within the brain but in much
greater quantities peripherally, especially in the liver. CNS-
produced IGF-I has important recognized roles during CNS
development and in adults in response to brain injury, but
serum IGF-I is crucial to a wide variety of functions within
the adult brain. These include promoting development,
neuronal excitability, myelin sheath synthesis, blood vessel
growth, neuronal survival, proliferation, differentiation, and
synaptogenesis [38, 39], as well as facilitating cerebral
glucose transport and metabolism. IGF-I promotes neuronal
plasticity and it is this influence upon the cellular substrate
of cognition that is thought to underpin the relationship
between IGF-I metabolism and cognitive function noted
with normal ageing, dementia, and delirium. It is a universal
cytoprotectant, with neurotrophic actions that maintain
neuronal functionality and contribute to the cellular mech-
anisms that provide the so-called “cognitive reserve” which
is so important in determining predisposition towards
cognitive failure in the face of precipitating physical insults.
In the case of delirium, this has been traditionally referred to
as “delirium readiness” and demonstrated in widely accepted
risk factor models for delirium [40, 41].
IGF-I stimulates proliferation and survival of many cell
types and is considered a universal cytoprotectant. It protects
against free radical damage and apoptosis [34, 42]. However,
this protective effect also applies to malignant cells and
underpins the association between IGF-I and breast cancer
and other tumors [43, 44]. In chronic inflammation an
interaction between IGF-I and other cytokines (especially IL-
6) has been suggested [45]. An interaction between cytokines
and IGF-I in acute inflammation or sepsis and a reduction of
IGF-I directly or indirectly thought TNF-α and/or IL-1β has
been reported [46, 47].
4. IGF-I and Ageing Processes
Disturbed IGF-I function is found in progeria syndrome
[48], and reduced IGF-I signaling in knockout mice strains
is associated with reduced lifespan [49]. Aging is associated
with a decrease in serum levels of IGF-I [50–53], while the
IGF-I/IGFBP-3 (insulin-like growth factor binding protein)
molar ratio is increased [54, 55]. Despite some discrepancies
in the levels of IGF-I in centenarians, for example [56, 57],
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most investigators agree that there is a decline of IGF-I levels
with aging, but a clear explanation is lacking [58]. Suggested
possibilities include reduced physical activity in the elderly
[59], decreased muscle volume and increased body fat [60],
poor nutritional status [61], or low levels of growth hormone
(GH) (in men) [62].
A decline in IGF-I has been linked with decline in
mobility in elderly women [63], and the combined effect of
low IGF-I and high IL-6 predicted mortality and disability
in a cohort of community-dwelling women [50]. Similarly,
the Framingham Heart Study [64] identified that low IGF-
I (as well as IL-6 and TNF-α) is associated with all-
cause mortality. However, other work has not replicated
this finding [65] where high IGF-I levels were associated
with increased all-cause mortality in elderly population. In
contrast, two more studies reported no relationship between
IGF-I levels and all-cause mortality [66, 67].
Other studies have investigated the relation of IGF-I with
cognitive impairment and dementia. IGF-I gene deletion
in humans is associated with mental retardation, micro-
cephaly, and deafness [68], while knockout IGF-I mice have
decreased brain size, disturbed glucose metabolism [69],
and loss of hippocampal granule neurons [70]. In clinical
settings, normalization of cognitive function is associated
with normalization of IGF-I levels in young adults [71] and
older patients [72] with growth hormone (GH) deficiency in
replacement therapy. Serum IGF-I levels correlate positively
with cognitive performance in studies of healthy elderly
subjects [56, 73, 74]. Studies in patients with Alzheimer’s
disease have been less consistent; reduced plasma levels
of IGF-I in plasma were found in patients with familial
AD, carriers of the Swedish APP/670/671 mutation, when
compared with controls from the same family without AD
[75], while reduced IGF-I levels were found by Murialdo et
al. [76] in AD patients compared to controls, and the IGF-
I levels were inversely correlated with cognitive impairment.
In contrast, IGF-I levels were unaltered or increased in other
studies of dementia patients [77–79]. IGF-I modulates many
aspects of beta-amyloid physiology, including synthesis, cel-
lular uptake, clearance, and degradation [80–82], can protect
and rescue neurons against potential neuronal death induced
by β-amyloid [42] and can modulate acetylcholine release in
hippocampal slices in vitro [83]. Moreover, administration
of IGF-I induces neurogenesis and increased progenitor cell
proliferation in the adult rat hippocampus [84, 85]. Thus,
it has been proposed that IGF-I may have a role in the
treatment of AD [86, 87].
The role of IGF-I in ageing and disease is under debate.
Reduced levels of IGF-I are linked to reduced cancer risk and
thus prolonging life [88], but conversely, low levels of IGF-I
are associated with increased risk for age-related conditions
like cognitive loss, dementia, frailty, tissue atrophy, and
vascular dysfunction. This apparent contradiction in roles
has not yet been resolved, perhaps because themany complex
biological actions of IGF-I involve different pathways and
other molecules.
Finally, interactions between IGF-I and key neurotrans-
mitter systems implicated in delirium pathogenesis have
been observed and include IGF-I’s potential to increase
choline acetyltransferase (CAT) levels, to prevent the loss
of CAT activity, to modulate acetylcholine release, and to
promote catecholaminergic and dopaminergic enzyme activ-
ities [34]. IGF-I has neurotrophic effects on dopaminergic
neurons in vivo [89], and the administration of IGF-I
in combination with other neurotrophic factors prior to
transplantation of dopaminergic neurons in rats was found
to prevent apoptosis and neuronal death [90]. More recently,
it has been observed that the N-terminal tripeptide of IGF-I
(GPE) is neuroprotective in dopaminergic neurons [36, 91,
92].
It seems from the above that IGF-I has close links with
cholinergic and dopaminergic systems which are emphasised
as the key neurotransmitters in prevailing neurochemical
models of delirium [93, 94]. IGF-I also has an important
relationship with proinflammatory cytokines [32, 95] that
are elevated in acute illnesses that are associated with
delirium.
Given that delirium is associated with older age and
dementia and IGF-I has important neurotrophic functions
in the brain and its involvement in the ageing process, IGF-I
has been a potential candidate for investigation in delirium.
The aims of the present paper are (a) to review evidence
from studies that have examined the relation of IGF-I
and delirium, (b) to discuss the possible pathophysiological
relationships between IGF-I and delirium (c) to discuss
the discrepancies between the studies and their relevance
to methodological differences, and (d) to recommend
approaches to clarifying the role of IGF-I in delirium patho-
genesis.
5. Studies of IGF-I in Delirium
5.1. Search Method for Relevant Studies. MEDLINE,
EMBASE, and Scopus databases were searched using the
keywords “delirium” or “acute confusion” combined with the
keywords “Insulin-like growth factor I” or “Sulfation factor”
or “Somatomedin-C”. In addition, this was supplemented
by a manual search of references from relevant papers. No
limits in language or year of publication were used.
5.2. Presentations of the Studies. Five relevant research papers
were retrieved (see Table 1). Wilson et al. [96] measured
baseline serum levels of IGF-I in a cohort of one hundred
acutely ill medical inpatients without delirium. Twelve
patients developed incident delirium during the follow-up.
Low IGF-I levels on admission were identified as a risk
factor for the development of delirium (OR: 0.822, CI: 0.69,
0.97, P = .027). Adamis et al. [30] examined serum IGF-I
levels in elderly medical inpatients with prevalent delirium
at admission. They found that patients with delirium had
significantly lower levels of serum IGF-I compared to
controls. In addition, incorporating a regression model, they
found that low IGF-I levels, female gender, and lack of APOE
epsilon 4 allele were predictors of recovery from delirium in
76.5% of cases, with a sensitivity of 0.77 and specificity of
0.75.
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Table 1: Studies of IGF-I in delirium.
Authors Settings Design n
Timing of IGF-I
measurement
Age (mean, sd)
Baseline
cognitive status
Findings
Wilson et al. [96] Medical Cohort 12 Baseline 84.5, 4.2 ∗MCI + normal
Low IGF-I risk
for incident
delirium
Adamis et al. [30] Medical Cross-sectional 22 Baseline 84.6, 6.5
50% with
dementia +
MCI + normal
Association of
IGF-I and
prevalence
delirium
Lemstra et al. [97] Orthopaedic Case Control 18 Baseline 79.3 ∗MCI + normal
No association
of IGF-I and
delirium
Adamis et al. [98] Medical Longitudinal 28
Baseline and
every 3 days
(max 4)
84.2, 6.3
50% with
dementia +
MCI + normal
Association of
IGF-I and all
delirium
Morandi et al. [99] ICU Cohort 40
Day before
assessment of
delirium
65 (median) No dementia
No association
between IGF-I
and next-day
delirium
∗
MCI: Mild cognitive impairment.
Furthermore, from the same cohort, but with repeated
measurements of IGF-I and other clinical and biological
factors, they found that low levels of IGF-I were associ-
ated with any delirium (prevalent or incident) during the
hospital stay and that low levels of IGF-I were associated
with more severe delirium [98]. Lemstra et al. [97], in
a case-control study, measured IGF-I levels preoperatively
in elderly patients admitted for hip surgery and found no
association between IGF-I levels and occurrence of post-
operative delirium. Finally, Morandi et al. [99] found that
previous-day IGF-I levels were not a risk factor for delirium
occurrence the following day in mechanically ventilated
medical Intensive Care Unit (ICU) patients. Overall, work
to date has identified a possible link between altered IGF-I
expression and delirium, but results have been contradictory.
6. Possible Pathophysiological Mechanism(s)
A range of possible mechanisms linking IGF-1 to delirium
pathogenesis have been suggested and include the following.
6.1. Direct Protection of Neurons By IGF-I. Although no
clear pathophysiological mechanism for delirium has been
identified, increasing evidence suggests that delirium may be
a neurotoxic state [21]. The neuroprotective actions of IGF-I
may thus be relevant to delirium pathogenesis. IGF-I exerts
neuroprotective actions in several types of neuronal cell types
including cortical, hippocampal, and dopaminergic neurons.
IGF-I protects neurons from cell death induced by various
sorts of damage, including hypoglycemia, hyperglycemia,
β-amyloid toxicity, osmotic stress, deprivation of specific
growth and survival factors, low potassium and ceramide.
However, the mechanisms of cell death after neuronal injury
are speculative and depend upon the particular methods
used to identify apoptotic cells [100]. Potential mecha-
nisms thus include oxidative stress, excitotoxicity, apoptosis,
autophagy, para-apoptosis, oncosis, and programmed or
accidental necrosis [101, 102]. IGF-I blocks apoptosis in
damaged neurons via several mechanisms. In the acute phase
after injury, IGF-I may delay apoptosis via activation of
PI3K/Akt kinase and Ras/Raf/MEK/ERK pathways [103] and
at a later second stage via pathways that are protein synthesis
dependent (like bcl-xL) and linked to longer term survival
[101, 104]. Although the intracellular pathway of IGF-I
receptor-dependent activation of the kinase Akt is a well
defined mechanism, more recent studies support that, even
in the absence of Akt and MEK dependent signaling, IGF-I
can still prevent apoptosis but via another mechanism that
requires p110a (a member of the phosphoinositide-3-kinase
(PI3K) class) [105]. Similarly, it is proposed that neurons
are directly protected by IGF-I and not via additional
trophic support from glia [101], although more recent work
indicates that glial cells are also major mediators of the
protective actions of IGF-I [106]. In addition, it has been
proposed that IGF-I is an important factor for promoting
neural plasticity, neurogenesis, andmemory such that altered
IGF-I activity may have a direct impact upon the integrity of
cellular processes that underpin cognition [107]. Improve-
ment in behavioral and cognitive outcome was observed
after administration of IGF-I in brain-injured animals [108].
Similarly, mutant mice with IGF-I deficiency show increased
vulnerability to insult together with other brain deficits
such as reduced neurogenesis and memory impairment,
but these deficits can be reversed with administration of
exogenous IGF-I [106]. In summary, low levels of IGF-I
may increase the vulnerability of neurons and thus induce
delirium, but, as IGF-I levels are increased during delirium
by any mechanism(s), beneficial effects of IGF-I may assist in
recovery from delirium.
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6.2. Dysregulation of the Somatotropic Axis. IGF-I has a piv-
otal role in the GRH/somatostatin-growth hormone IGF-
I axis, and its release is controlled by various feedback
mechanisms. GH controls the secretion of IGF-I and is itself
controlled by two hypothalamic peptides: grown hormone
releasing hormone (GHRH) which stimulates the synthesis
and secretion of GH, and Somatostatin (GHIH) which
inhibits it. IGF-I expression in the liver is modulated by
GH, but this GH-stimulated IGF-I expression has also been
observed in brain tissue. Increased IGF-I mRNA levels have
been found in response to GH in dwarf mice, and, in
hypophysectomized rats, the expression of IGF-I mRNA in
the brain was four time less than in normal rats [109, 110].
Levels of IGF-I expression recovered to near normal after
injection of human GH into the hypophysectomized rats
[110]. It seems that IGF-I is a major determinant of growth
under GH modulation [111], and its expression in the brain
is also GH dependent. There is also an age-related decrease
in the secretion of GH, which is principally the result of a
reduction of the net stimulation of the pituitary gland by
hypothalamic neurons rather than a lack of the secretory
capacity of the pituitary gland [112]. In addition, frailty is
associated with reduced levels of GH [113], and therapy with
GH can increase energy, mood, concentration, memory, and
general vitality. The effects of GH on cognition may reflect a
direct effect of GH in the brain [112]. The role of IGF-I in
delirium may reflect a wider disturbance of the somatotropic
axis that can be clarified by studies that account for relative
levels of IGF-I, GH, and its regulatory hormones.
6.3. Glucocorticoids. High levels of glucorticooids, dysreg-
ulation of HPA axis, and high levels of cortisol also have
been linked to delirium occurrence [32, 114]. IGF-I and
glucocorticoid metabolism is also linked. Treatment of brain
neuronal cultures with dexamethasone reduces IGF-I mRNA
levels by 60% [115]. Similarly, dexamethasone decreases
IGF-I mRNA levels in rat C6 glioma cells [116]. It has been
suggested that this glucocorticoid-induced reduction in IGF-
I production occurs at the level of transcription. However, it
is not clear if this reduced IGF-I expression by glucocorticoid
is a result of a direct interaction between the activated
glucocorticoid receptor and the IGF-I promoter [117].
6.4. Cytokine Effects. Delirium is strongly associated with
infection and other inflammatory process [118]. Therapeutic
use of cytokines (mainly interferons) can induce symptoms
of delirium as an adverse effect [119]. It has been suggested
that alterations of the aging immune response and the dys-
regulation of cytokines are the result of an age-related
decrease of IGF-I and GH [89]. Animal studies indicate
that IGF-I can activate the immune system [120], while
studies in humans indicate that IGF-I levels can be regulated
by IFN-γ [121] and that IGF-I has significant interactions
with a variety of cytokines including IL-6, TNF-α, and IL-
1β [38, 45–47]. Thus, an emerging possibility is that direct
interactions between cytokines and IGF-I may be relevant
to their role in delirium. However, research to date has
focused on a limited range of cytokines and their receptors
or included a single measurement of IGF-I.
7. Methodological Critique of the Studies
7.1. Sample Sizes. All of the studies had small samples (from
12 to 40 delirious cases; see Table 1). As IGF-I levels are
prone to considerable interindividual differences due to both
genetic and environmental influences, these small sample
sizes are especially prone to type II errors. Moreover, given
that IGF-I has so many functions, interactions, homeostatic
sensitivities that confounders abound and the small sample
in some studies may have precluded the demonstration of
other significant risk factors more important than IGF-I
levels.
7.2. Selection Bias Based on Consent/Assent Issues. Delirium
impacts considerably upon cognitive faculties that are rele-
vant to capacity. In many cases, the principles described in
the Declaration of Helsinki can allow for delirious patients
to participate in research studies, but nevertheless the ethical
challenges of the informed consent process, uncooperative-
ness in agitated or psychotic patients can impact upon
ability to assent, and availability of proxy sources of consent
[122] can impact upon recruitment [123]. Moreover, it
is the nature of delirium to be fluctuating and transient,
sometimes clearing in the time it takes to obtain assent from
the patient’s proxy [124]. Including only delirious subjects
with capacity to consent can lead to selection bias with
reduced generalisability of results. Such effects have been
demonstrated in the Adamis et al. sample, where exclusion
from analysis of incapacitated participants showed that the
significant association of IGF-I and delirium were no longer
evident [125]. Thus, the informed consent process can be an
important factor which has been underestimated in delirium
studies and is an important source of bias.
7.3. Longitudinal Design. The natural history of delirium
is that of an often fluctuating condition. Similarly, IGF-
I concentrations fluctuate according to many factors (e.g.,
levels of other hormones, nutrition, cytokines). Free IGF-
I has an estimated half-life of 10–12min, while the bound
form (with IGFBP’s) has an increased half-life in the range
of 12–15 hours [126]. As such, longitudinal research designs
are required in order to accurately capture the course and
outcome of delirium and related factors, but the bulk of work
to date has included assessments of IGF-I at a single time
point rather than serial assessments.
7.4. Confounding Factors. Age is an important factor which
influences IGF-I levels. Wilson et al. [96] studied an elderly
population (75 years old and above), while that of Adamis
et al. [30, 98] was 70 years and older. In contrast, Morandi
et al. [99] studied a relatively younger population. However,
all of the studies have controlled for age in their analyses
and, as such, age span could not explain the different results.
Albeit we need to be cautious with this interpretation as all of
the studies involved small samples of average age more than
65. Similarly, severity of illness has been adjusted in all of the
above studies, and, although the study of Morandi et al. [99]
included more severely ill participants (as measured with the
APACHE II score), existing evidence does not indicate that
6 Journal of Aging Research
the severity of illness is amajor factor explaining the disparity
in study findings.
In addition, cognitive impairment can also impact upon
findings and may contribute to discrepancies in reported
studies. Morandi et al. [99] excluded participants with
previous dementia. Lemstra et al. [97] and Wilson et al.
[96] included participants with mild cognitive impairment,
while, in the studies of Adamis et al. [30, 98], half of those
studied had documented with DSM-IV dementia. Although,
these differences in cognitive status may contribute to the
differences in findings across studies, and low levels of
IGF-I are associated with preexisting dementia rather than
delirium, it can also be argued that if dementia is a risk
factor of delirium and if IGF-I is associated with dementia
and cognitive decline, we could expect that low levels of IGF-
I will be associated with delirium. It is relevant that studies
that found an association adjusted for cognitive impairment
indicate that both cognitive impairment and low IGF-I levels
were independent risk factors for delirium.
The studies of IGF-I have not been matched by similar
work investigating the role of related substances such as
growth hormone (GH) and IGFBPs. GH has anabolic actions
and increases plasma IGF-I in a dose-dependent way, but
with a plateau effect [127]. A previous study [128] found
that cerebrospinal fluid somatostatin (Growth hormone
Inhibiting hormone) levels were significantly lower both
during incident delirium and at 1 and 4 year followup.
Although this finding does not directly link delirium with
increased GH levels, it does point towards disturbance of
the somatotropic axis during delirium. Indeed, in critically
ill patients, low circulating IGF-I is associated with high GH
levels [129]. However, exogenous administration of human
growth hormone in frail elderly women after hip operation
is associated with increased levels of both IGF-I and IGFBP-3
[113]. Thus, it is not clear how GH and IGF-I interact during
delirium.
Similarly, IGF-I levels are also regulated by binding to
multiple circulating proteins with IGFBP-3 accounting for
80–90% of IGF-I binding [58]. IGFBP-3 is a circulating IGF-I
reservoir that may have neuroprotective and cell survival
actions that are independent from those related to IGF-I
[130]. IGFBP-1 is also an important regulator of IGF-I
and has both inhibitory and enhancing effects on IGF-I.
Moreover, IGFBP-1 levels are increased in old age and
in those exposed to severe stress, nutritional deprivation,
muscle wasting, and inflammation [131]. In addition, insulin
is another important factor that has not been examined to
date. Insulin enhances the production of IGF-I and increases
IGF-I levels in conditions where GH levels are decreased [34].
Accounting for all of the factors that can influence IGF-I
levels is challenging, but studies to date still have not
investigated many important basic factors such as GH and
IGFBPs.
7.5. Outcome. Most of the reported studies examined IGF-I
levels as a risk factor for delirium. One study investigated
the levels of IGF-I together with other factors (cytokines
and APOE genotype) as predictors for recovery [30]. Inter-
estingly those delirious patients with lower initial levels of
IGF-I were also those who finally recovered from delirium.
Although the results of this study need to be interpreted with
caution because of the small sample size, it seems that a feed-
back mechanism maintains IGF-I levels above a minimum,
and, in those with delirium who ultimately recover IGF-I
levels steadily increase over time.
Ultimately, in addition to the possibility than IGF-I may
be a causal factor in delirium, its neuroprotective effects
point to a possible role in facilitating recovery from delirium.
8. Conclusions and Recommendations
The widespread role of IGF-I in regulating bodily metabolic
and brain functioning, as well as its capacity to connect
these systems to allow for adaptive response to changing
environmental demands, makes it an attractive candidate for
study of a potential role in the pathophysiology of delirium—
a condition that reflects widespread brain dysfunction in
response to a variety of peripheral metabolic stressors.
Studies to date indicate that IGF-I can have an important role
in the cellular processes that underpin ageing and cognition,
but specific studies of IGF-I in delirium have produced
somewhat conflicting results. The nature of this relationship
may be complex in that IGF-I levels may be relevant to
delirium proneness, the occurrence of delirium episodes,
and/or factors relevant to delirium recovery. A direct causal
relationship of disturbed IGF-I expression with delirium
could be identified by cross-sectional studies, although con-
founding factors such as age, frailty, baseline cognitive status,
as well as selection bias need to be considered in interpreting
results. More complex relationships require longitudinal
studies in order to clarify the relevance of IGF-I to delirium
status over time. More pragmatic observational studies are
required that include greater numbers of representative
patients and that investigate multiple biological factors to
clarify the extent to which the role of IGF-I as a predictive
factor for delirium is an independent or surrogate factor.
Greater understanding of the role of IGF-I and related factors
in delirium pathogenesis can inform efforts to design clinical
trials involving administration of exogenous IGF-I.
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